WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)

Christophe Le Tourneau,¹ Allan Hackshaw,² Jean-Yves Blay,3 Jan Geissler,4 Clare Turnbull,5 Camille Perret,⁶ Olga Skatkova,⁶ Martina von Meyenn,⁶ Rodrigo Dienstmann⁷

¹Institut Curie, Paris, France; ²UCL Cancer Institute, London, UK; 3Centre Léon Bérard, Lyon, France; ⁴Patvocates, Munich, Germany; ⁵The Institute of Cancer Research, London, UK; ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁷Oncoclínicas Precision Medicine, Oncoclínicas Grupo, São Paulo, Brazil



Summary

WAYFIND-R will inform on best practice for NGS-based treatment decisions by clinicians, foster global collaborations between cancer centers (enabling robust conclusions to be drawn regarding outcome data), aid understanding of disparities in patients' access to advanced diagnostics and therapies, and ultimately drive advances in precision oncology

https://bit.ly/3voA3jU https://bit.ly/3laGUjE

Copies of this poster obtained through quick response and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.





Rare molecular cancer subtypes and evolving biomarker knowledge pose difficulties in traditional clinical trials for NGS-based molecular therapy¹



Collecting RWD from patients can help to elucidate the effectiveness of targeted therapies, MTBs, and NGS-based genomic profiling²




WAYFIND-R (NCT04529122), a global, prospective, longitudinal, generalizable registry, with NGS and standardized data collection to enhance data quality and limit data missingness

Characterizes the treatments and clinical course of patients with solid tumors



Provides a data research platform to evaluate real-world treatment decisions and outcomes

Supports the design and conduct of epidemiologic research and clinical trials





Eligibility criteria

Adults with any type/stage of solid tumor who have been profiled with NGS (all clinically validated tests of any size)


Academic centers, community hospitals, and private clinics with regular MTBs and where NGS is common practice

Prior or current diagnosis of a hematologic malignancy

Computerized systems at three levels

Patient-level dataset

Global dataset visualization dashboard Patient-level dataset in a global oncology RWD collaboration platform



Expansion phase (>35 countries; ~15,000 patients by 2026)†



Enables physicians to

generate local molecular

epidemiology data and track

institutional cohorts

12:8; 2. Lewis JRR, et al. JCO Precis Oncol 2017; 1:1-11.



Allows physicians to find


similar patient pools,

providing insights for clinical

decision-making



Supports correlative clinico-genomic analyses to answer scientific questions*



Medical information collected at baseline and at least every

6 months across the entire patient journey (Supplement)

*Access granted by an independent data access committee. To optimize data sharing while meeting General Data Protection Regulation and local data privacy requirements, the platform will use advanced technology to enable data privacy by design

Acknowledgments

Conflicts of interest

CLT has received grants/contracts from MSD, has received travel expenses from MSD, BMS, and AstraZeneca, has received honoraria from and performed a consulting/advisory role for BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Rakuten, Seattle Genetics, and AstraZeneca, and has been paid by Roche as an external consultant. Please refer to the Supplement for all author conflicts of interest. This analysis was sponsored by F. Hoffmann-La Roche Ltd.

Abbreviations: MTB, molecular tumor board; NGS, next-generation sequencing; RWD, real-world data. References: 1. Malone ER, et al. Genome Med 2020:

Research support for third-party writing/printing assistance for this poster, furnished by Stephen Salem, BSc, of Healt Interactions, was provided by F. Hoffmann-La Roche Ltd.

Please contact the lead author at Christophe.LeTourneau@curie.fr for permission to reprint and/or distribute. Presented at the AACR Annual Meeting 2022, April 8-13, 2022, New Orleans, LA, USA.